WP
GILD icon

Westmount Partners’s Gilead Sciences GILD Stock Holding History

Westmount Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$365K Buy
2,887
+44
+2% +$5.8K 0.08% 188
2026
Q1 		$396K Buy
2,843
+9
+0.3% +$1.26K 0.1% 170
2025
Q4 		$348K Sell
2,834
-280
-9% -$34K 0.09% 176
2025
Q3 		$346K Buy
3,114
+4
+0.1% +$455 0.09% 176
2025
Q2 		$345K Buy
3,110
+10
+0.3% +$1.06K 0.09% 168
2025
Q1 		$347K Sell
3,100
-213
-6% -$22K 0.11% 161
2024
Q4 		$306K Buy
3,313
+243
+8% +$21.9K 0.09% 170
2024
Q3 		$257K Buy
3,070
+5
+0.2% +$382 0.08% 184
2024
Q2 		$210K Buy
3,065
+6
+0.2% +$400 0.07% 200
2024
Q1 		$224K Sell
3,059
-137
-4% -$10.5K 0.08% 187
2023
Q4 		$259K Sell
3,196
-107
-3% -$8.33K 0.11% 158
2023
Q3 		$248K Buy
3,303
+260
+9% +$20K 0.11% 163
2023
Q2 		$235K Sell
3,043
-95
-3% -$7.58K 0.1% 158
2023
Q1 		$260K Sell
3,138
-117
-4% -$9.69K 0.12% 149
2022
Q4 		$279K Buy
+3,255
New +$258K 0.15% 140

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Westmount Partners's GILD Position: Q2 2026 in Review

Westmount Partners increased its Gilead Sciences (GILD) stake by 1.5% in Q2 2026, buying an estimated $5.8K and bringing the position to 2,887 shares worth $365K. The position accounts for 0.08% of the portfolio, ranked #188.

Westmount Partners first reported a position in GILD in Q4 2022 and has held it in 15 quarters since. The position peaked at $396K in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Westmount Partners held 2,887 shares of Gilead Sciences worth $365K as of Q2 2026.
  • Westmount Partners bought 44 Gilead Sciences shares in Q2 2026, an estimated $5.8K.
  • Gilead Sciences made up 0.08% of Westmount Partners's portfolio in Q2 2026, its #188 holding.
  • Westmount Partners first reported a position in Gilead Sciences in Q4 2022 and has held it in 15 quarters since.
  • Westmount Partners's Gilead Sciences position peaked at $396K in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Westmount Partners's 13F filing for Q2 2026, filed 7 Jul 2026.